MedPath logo

DIFFLAM LOZENGE 3 mg

Pharmacy Only
Drug type: Therapeutic
ATC code: A01AD02
Dosage form: LOZENGE
Route of administration: ORAL
Active ingredient: BENZYDAMINE HCl; BENZYDAMINE HCl

INDICATIONS

For the temporary relief of painful conditions of the oral cavity including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, post-orosurgical and periodontal procedures, pharyngitis, swelling, redness and inflammatory conditions.

CONTRAINDICATIONS

Patients with known hypersensitivity to benzydamine or to any of the components of the vehicle.

DOSAGE AND ADMINISTRATION

Difflam Anti-inflammatory Lozenges should not be chewed. They should be slowly dissolved in the mouth. One lozenge should be sucked slowly every one to two hours as required up to a maximum of 12 lozenges per day. Uninterrupted treatment should not exceed seven days.

With Impaired Renal Function

Since absorbed benzydamine and its metabolites are excreted in the urine, the possibility of systemic effects should be considered in patients with severe renal impairment.

With Impaired Liver Function

Since absorbed benzydamine is highly metabolised in the liver the possibility of systemic effects should be considered in patients with severe hepatic impairment.

Registrant
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
Approval Date
1993-04-29
Approval Number
SIN07411P
Manufacturer
Unique Pharmaceuticals Laboratories
Licence Holder
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED